Plasma Amyloid-BetaPeptides in Acute Cerebral Ischemia: A Pilot Study

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 4, 2012, Pages 238-245

  Bibl, Mirko ^a   Welge, Volker ^a   Schmidt, Holger ^b   Esselmann, Hermann ^a   Mollenhauer, Brit ^b   Lewczuk, Piotr ^c   Otto, Markus ^d   Kornhuber, Johannes ^c   Wiltfang, Jens ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Acute cerebral ischemia; Amyloid peptides; Biomarkers

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; ALCOHOLISM; ARTICLE; ASTHMA; BINSWANGER ENCEPHALOPATHY; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DEPRESSION; DIABETES MELLITUS; FOCAL EPILEPSY; HEART ARRHYTHMIA; HEART ATRIUM THROMBOSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; IMMUNOBLOTTING; IMMUNOPRECIPITATION; ISCHEMIC HEART DISEASE; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NEPHROLITHIASIS; PILOT STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYNEUROPATHY; QUANTITATIVE ANALYSIS; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SMOKING; STROKE; TENSION HEADACHE; VEIN PUNCTURE; ACUTE DISEASE; BLOOD; MIDDLE AGED; NONPARAMETRIC TEST;

ACUTE DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MIDDLE AGED; PILOT PROJECTS; STATISTICS, NONPARAMETRIC;

EID: 84864025266     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21511     Document Type: Article

References (20)

1. Saenger AK, Christensen RH. Stroke biomarkers: Progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem 2010;56:1-13.
2. Castellanos M, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007;24:7-15.
3. Wiltfang J, Esselmann H, Bibl M, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and patients with chronic neuroinflammation. J Neurochem 2002;81:481-496.
4. Lewczuk P, Esselmann H, Bibl M, et al. Electrophoretic separation of amyloid β (Aβ) peptides in plasma. Electrophoresis 2004;25:3336-3343.
5. Van Oijen M, Hofmann A, Soares HD, Koudstaal PJ, Breeteler MMB. Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: A prospective case-cohort study. Lancet Neurol 2006;5:655-660.
6. Bibl, M, Esselmann H, Mollenhauer B, et al. Blood-based neurochemical diagnosis of vascular dementia: A pilot study. J Neurochem 2007;103:467-474.
7. Gurol ME, Irizarry MC, Smith EE, et al. Plasma β-amyloid and white matter lesions in AD, MCIand cerebral amyloid angiopathy. Neurology 2006;66:23-29.
8. Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not Abeta42 correlates with phospho-Tau in patients with low- and high CSF-Abeta40 load. J Neurochem 2007;101;1053-1059.
9. World Medical Organisation. Declaration of Helsinki. Brit Med J 1993;313:1448-1449.
10. World Health Organisation. Stroke-1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHOTask Force on Stroke and other Cerebrovascular Disorders. Stroke 1989;20:1407-1431.
11. Adams HPJ, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
12. Janek K, Rothemund S, Gast K, et al. Study of the conformational transition of Abeta(1-42) using D-amino acid replacement analogues. Biochemistry 2001;40:5457-5463.
13. Bibl M, Esselmann H, Otto M, et al. Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβpeptides. Electrophoresis 2004;25:2912-2918.
14. Xu F, Previti ML, Van Nostrand WE. Increased severity of hemorrhage in transgenic mice expressing cerebral protease nexin-2/amyloid beta-protein precursor. Stroke 2007;38:2598-2601.
15. Xu F, Previti ML, Nieman MT, Davis J, Schmaier AH, Van Nostrand WE. AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. J Neurosci 2009;29:5666-5670.
16. Ponte P, Gonzalez-DeWhitt P, Schilling J, et al. A new A4 amyloid mRNAcontains a domain homologous to serine proteinase inhibitors. Nature 1993;331:525-527.
17. Broze GJ Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-7546.
18. Del Zoppo G. Amyloid-β may keep clots away. Nat Med 2009;15:1132-1133.
19. Gomis M, Sobrino T, Ois A, Millan M, et al. Plasma β-Amyloid is associated with the diffuse Small Vessel Disease subtype. Stroke 2009;40:3197-3201.
20. Van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesion. Ann Neurol 2004;55:570-575.